Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
Enspryng (satralizumab) as a potential treatment for generalized myasthenia gravis (gMG). This drug has been developed in collaboration with Roche RHHBY. The Tokyo-based company evaluated the Roche-partnered drug in the phase III LUMINESCE study in patients with gMG, a rare autoimmune disease that leads to muscle weakness. While patients who received the Chugai-Roche partnered drug did show statistically significant improvements following 24 weeks of treatment, the results fell short of the companies' “expectations on the degree of clinical benefit." Detailed results from the LUMINESCE study are expected at the American Academy of Neurology (AAN) 2024 Annual Meeting on Apr 15. The above results benefit Argenx, which markets Vyvgart (efgartigimod). The intravenously-administered Argenx drug was approved by the FDA in December 2021 to treat adults with gMG who test positive for the anti-acetylcholine receptor (AChR) antibody. Last June, the agency approved a subcutaneous formulati
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Should You Hold Immunovant (IMVT)? [Yahoo! Finance]Yahoo! Finance
- Here's Why You Should Add Immunovant (IMVT) to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- What Makes Immunovant (IMVT) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
IMVT
Earnings
- 2/12/24 - Beat
IMVT
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- IMVT's page on the SEC website